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Abstract
Background: We aimed to describe the longitudinal 
changes in bone mineral content and influencing factors, 
in children with cystic fibrosis (CF).
Methods: One hundred children (50 females) had dual 
X-ray absorptiometry (DXA) performed. Of these, 48 and 
24 children had two to three  scans, respectively over 
10 years of follow-up. DXA data were expressed as lumbar 
spine bone mineral content standard deviation score 
(LSBMCSDS) adjusted for age, gender, ethnicity and bone 
area. Markers of disease, anthropometry and bone bio-
chemistry were collected retrospectively.
Results: Baseline LSBMCSDS was > 0.5 SDS in 13% chil-
dren, between − 0.5; 0.5 SDS, in 50% and  ≤  − 0.5 in the 
remainder. Seventy-eight percent of the children who 
had baseline LSBMCSDS > − 0.5, and 35% of the children 
with poor baseline (LSBMCSDS < − 0.5), showed decreas-
ing values in subsequent assessments. However, mean LS 
BMC SDS did not show a significant decline in subsequent 
assessments (− 0.51; − 0.64; − 0.56; p = 0.178). Lower forced 
expiratory volume in 1 s percent (FEV1%) low body mass 
index standard deviation scores (BMI SDS) and vitamin D 
were associated with reduction in BMC.
Conclusions: Bone mineral content as assessed by DXA 
is sub-optimal and decreases with time in most children 
with CF and this study has highlighted parameters that 
can be addressed to improve bone health.
Keywords: bone mineral content; children; cystic fibro-
sis; dual-energy X-ray absorptiometry (DXA); longitudinal 
study; markers of disease.
Introduction
Cystic fibrosis (CF) is an autosomal recessive disorder 
caused by defects in the cystic fibrosis transmembrane 
conductance regulator protein (CFTR) occurring at a fre-
quency of 1 in 3200 live births [1]. In addition to expres-
sion of CFTR in a variety of epithelial cells, its expression 
has been found in osteoblasts but its precise role in these 
cells remains to be elucidated [2]. People with CF, espe-
cially those with advanced disease, are exposed to a 
number of factors, including chronic inflammation, inad-
equate nutrition, vitamin D deficiency, reduced physical 
activity, hypogonadism and glucocorticoid exposure that 
will increase their risk of adverse bone health [3]. Approx-
imately, a quarter of young adults with CF may have oste-
oporosis and the prevalence of radiologically-confirmed 
fractures may be about 20% [4–6]. However, children 
with CF do not seem to have an increased risk of fractures 
and cross-sectional studies suggest that deficit in bone 
mineral content only seems to become prevalent in young 
adulthood [7]. With continuing improvements in therapy, 
increasing numbers of children are now surviving into 
adulthood and the ongoing concerns about bone health 
have led to recommendations advocating close monitor-
ing of bone health in older children by dual-energy X-ray 
absorptiometry (DXA) coupled with close monitoring and 
replacement of vitamin D [8, 9]. However, the evidence 
base for such practice is lacking and a recent Cochrane 
review has highlighted the need for more research [10]. 
The aim of this study was to perform a retrospective 
review of the bone health monitoring program at one CF 
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centre, assess the extent of abnormality of bone health 
and then examine the presence of any factors that deter-
mine longitudinal changes in bone mineral content as 
assessed by DXA.
What’s known on this subject
Older children and adolescents with cystic fibrosis may 
have poorer bone mineral content than younger patients.
What this study adds
 – Bone mineral content decreases with time in children 
with CF
 – The reduction is associated to low FEV1% and low 
body mass index standard deviation scores (BMI SDS)
 – Low vitamin D may also play an important role when 
associated with a high parathyroid hormone (PTH)
Patients and methods
Description of subjects
In a retrospective analysis of 289 children with CF, receiving either 
full care or shared care at the Royal Hospital for Sick Children Glas-
gow (RHSC) and one of its affiliated hospitals, we selected children 
that had at least one DXA scan performed over a period of 10 years 
(January 2003–June 2013). Children were included if they had the 
diagnosis of CF by molecular diagnosis, were aged between 8 and 
18  years and had at least one DXA assessment performed in the 
RHSC. Children were excluded if clinical data were not available. 
Supplemental feeding was defined as the child receiving enteral 
feeding at a minimum frequency of once a week in the month prior 
to the scan. Oral/inhaled corticosteroid was defined as corticoster-
oid treatment during the year previous to the scan. Forced expiratory 
volume in 1 s percent (FEV1%) was used as a marker of pulmonary 
function and was assessed using a spirometer (Jaeger Masterscreen 
Body, CareFusion, San Diego, CA, USA). Impaired glucose tolerance 
was defined, according to the American Diabetes Association guide-
lines, as a fasting plasma glucose level of less than 7 mmol/L and a 
2-h plasma glucose level of 7.8 to 11 mmol/L. Diabetes was diagnosed 
when a fasting glucose level was 7 mmol/L or higher or a 2-h plasma 
glucose level of more than 11 mmol/L [11].
Auxology
Anthropometric data were collected from the clinical records and 
height and BMI were expressed as SDS using the UK growth reference 
[12]. Given the lack of availability of puberty data, age at peak height 
velocity (PHV) was used as a marker of pubertal progress [13]. The 
mean age increment was 1.2 years (range 0.42, 1.86) and the height 
gain (cm) was divided by this age increment for each year of age from 
9 to 16 years, to obtain height gain per month and estimate the annu-
alised height velocity.
Segregation status
The segregation status of children was assessed by categorisation 
into three classes: chronically colonised with Pseudomonas aerugi-
nosa (PSA) or Burkholderia cepacia (CA) intermittently colonised with 
PSA and PSA naïve. Chronic colonisation with PSA or BC was defined 
as PSA or BC in sputum in the past 6 months, with three or more iso-
lates in the past 12 months post-eradication. Intermittent colonisa-
tion with PSA was defined as no PSA in current sputum cultures and 
clear of PSA for more than 6 months, but intermittent isolates in past; 
or currently has PSA in sputum or in the past 6 months but cannot yet 
be classed as chronically colonised.
Bone biochemistry
Biochemical data at the time of the DXA scan were collected from 
local records. PTH was analysed by chemiluminescent microparti-
cle immunoassay (CMIA) on an Abbott Architect ci8000 (ABBOTT, 
Wiesbaden, Germany). Serum PTH levels  ≥  7.5 pmol/L (70  pg/mL) 
were considered to be significantly elevated. Vitamin D (25-hydrox-
yvitamin D2 and 25-hydroxyvitamin D3) status was measured by liq-
uid chromatography tandem mass spectrometry (LC-MS/MS) using 
commercial standard in human serum (Chromsystems, München, 
Germany). Using the British Paediatric and Adolescent Bone 
Group’s position statement, vitamin D deficiency was defined when 
serum  vitamin D (25OHD) levels were < 25  nmol/L, insufficiency 
when levels were 25–50 nmol/L and sufficiency at a concentration 
greater than 50 nmol/L [14].
DXA
DXA of the lumbar spine (LS, L2–L4) and total body (TB) using Lunar 
Prodigy (GE Medical Systems, Waukesha, WI, USA) was performed as 
part of routine clinical practice. As outlined in previous studies [15, 
16], using the manufacturer’s software, absorptiometry was related 
to bone mineral content (BMC) expressed in grams of ashed calcium 
hydroxyapatite equivalents and to grams per centimetre squared of 
BMD corresponding to BMC divided by the bone area scanned. Lunar 
software calculated an ethnicity; age- and gender-matched BMD SDS 
using a reference population of more than 2,000 American children 
between the ages of 5 and 19 years evaluated by Lunar Prodigy. The 
reference data are comparable to recently published data on Dutch 
children by van der Sluis et al. [17]. They provide age- and gender-
matched BMC and bone area values for each age and gender band 
between 5 and 19 years. By linear interpolation, these data allowed 
calculation of a predicted and a percentage predicted bone area for 
age and gender (pp bone area). A child with short stature should 
have small bones and would have a low pp bone area. The reference 
data also allows a comparison of the actual BMC of the patient with 
the predicted BMC for a subject of the patient’s gender and bone area. 
This allows the calculation of a BMC SDS. A child with osteopenia 
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should have thin bones, irrespective of whether the bones are small 
or large, and would have a low BMC SDS.
Ethics
As the study simply analysed data that was routinely collected as part 
of the clinical care of the patient, the study did not require informed 
consent and was approved as an evaluation of health care delivery.
Statistical analysis
Descriptive statistics are outlined for all variables assessed. Means 
and standard deviations (SDs) were calculated for all normally 
distributed continuous measures. Data were analysed with SPSS 
20 (SPSS Inc, Chicago, IL, USA). Baseline (T0) was assigned at the 
time of the first DXA assessment for each child while T1 and T2 were 
noted as the time when each child had a second and third DXA 
assessment. The Student’s t-test and repeated-way ANOVA for three 
samples were used for comparing variance. Hierarchical regression 
models (backward method) were used to assess the factors that 
influence baseline LS BMC SDS and also the factors that influence 
change in bone mass. The difference between two DXA assessments 
was calculated as ∆ LS BMC SDS = T1 − T0 and T2 − T1. Further, as 
the time between DXA assessments was variable, this difference 
was annualised by dividing it with the time between assessments 
in decimal years. This annualised ∆ LS BMC SDS was used as the 
dependent variable in hierarchical regression model (backward 
method) to assess longitudinal change in BMC. The predictors of 
change in BMC were considered in variables measured at base-
line, T1, T2 and were calculated as differences, (i.e. ∆ FEV1% = T1 
FEV1% − T0 FEV1%), for all variables.
Results
Out of the total 289 children with CF in follow-up at RHSC, 
103 children had at least one DXA scan performed and 
were included in the study. One child with congenital 
pseudohypoaldosteronism was excluded. Clinical data 
were not available for two children. Of the remaining 100 
children (50 females), 48 had two DXA scans, 24 children 
had three DXA scans during the 10-year period. Mean age 
at the time of first DXA scan was 12 years (SD = 1.89).
Anthropometry
Descriptive clinical data for the children with CF at 
baseline are presented, in Table 1, for all children and 
Table 1: Comparative descriptive features of children at baseline: those who had a single DXA assessment and those who had repeated 
(2 or 3) DXA assessments.
 
 
All 
 
Single assessment 
 
2 DXA assessments  p-Value
n  Mean  SD n  Mean  SD n  Mean  SD
Decimal age, years   100  12.04  1.89  52  12.90  2.02  48  11.11  1.21  0.000
Age at PHV, years   85  12.24  1.39  41  12.22  1.39  44  12.25  1.42  0.920
Growth in cm at PHV   85  7.68  2.01  47  7.41  2.23  48  7.96  1.75  0.191
Height SDS   96  − 0.23  1.05  52  − 0.54  1.01  48  0.09  1.02  0.003
BMI SDS   96  − 0.13  1.12  48  − 0.27  1.09  48  0.01  1.16  0.231
Vitamin D, nmol/L   94  45.38  24.98  48  42.23  22.99  46  48.70  26.78  0.213
PTH, pmol/L   84  4.98  3.24  41  5.67  3.61  43  4.33  2.74  0.060
FEV1%   98  82.47  19.36  50  79.30  19.83  48  85.77  18.50  0.098
LS BMC SDS   100  − 0.24  0.61  52  − 0.15  0.53  48  − 0.34  0.68  0.115
TB BMC SDS   100  0.13  0.43  52  0.16  0.39  48  0.11  0.47  0.554
Oral corticosteroids   100   4 (4%)   52   3 (6%)   48   1 (2%)  
Inhaled corticosteroids   100   45 (45%)   52   25 (48.1%)   48   20 (42%)  
Impaired glucose tolerance   100   25 (25%)   52   14 (26.9%)   48   11 (23%)  
Supplemental feeding   100   10 (10%)   52   8 (15%)   48   2 (4%)  
Segregation status:   88   17/51/20   44   5/27/12   44   12/24/8  
Chronically colonised PSA or BC/
Intermittently colonised PSA/PSA naive
    (19/58/23%)     (11/62/27%)     (27/55/18%)  
Gender, males/females   100   50%/50%   52   40%/60%   48   60%/40%  
n, number of children; PHV, peak height velocity; SDS, standard deviation score; PTH, parathyroid hormone; BMC SDS, bone mineral content 
standard deviation score; LS, lumbar spine; TB, total body; FEV1%, forced expiratory volume in 1 s percent; PSA, Pseudomonas aeruginosa; 
BC, Burkholderia cepacia; intermittently colonised with PSA, patients had P. aeruginosa in sputum in the past or in the year of DXA, but not 
chronically colonised; PSA naive, patients never had Pseudomonas. All continuous variables are expressed as mean and standard devia-
tions, categorical variables are expressed as number of positive cases and (percentages). p-Value is calculated with independent sample 
t-test.
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separately the group that had a single DXA assessment 
(n = 52) versus those who had repeated DXA assessments 
(n = 48). On an average, DXA assessments were performed 
1.8  years apart (SD = 0.7). Significant differences were 
found between boys and girls at baseline in mean age 
at PHV, mean PHV and mean height SDS as seen in the 
general population.
Vitamin D, PTH status
Of the 94/100 children where a vitamin D level was avail-
able at baseline, 24% were deficient, and 39% were insuf-
ficient (Figure 1). Of the 84/100 children where a PTH level 
was available, 14% children had a value above 7.5 pmol/L 
(70  pg/mL). Vitamin D and PTH values were available 
simultaneously for 81/100 children. Of them, 49% had 
low vitamin D (insufficient and deficient) but normal PTH, 
while 12% had low vitamin D and high PTH.
On longitudinal analysis, 27% of the children were 
vitamin D deficient on one occasion, 17% on two occa-
sions and none on all three occasions (Figure 2A, B, C). 
Thirty-four percent of the children were vitamin D insuf-
ficient on one occasion, 27% on two occasions and 5% on 
three occasions.
Bone mineral content
In the 100 children, baseline LS BMC SDS was more than 
0.5 in 13% of the children; 50% had LS BMC SDS between 
− 0.5 and 0.5, while 37% had SDS  ≤  − 0.5 (Figure 1). Ten 
children (10%) had LS BMC SDS below − 1 at baseline. 
In longitudinal analysis (across 3 DXA assessments) the 
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Figure 1: Baseline bone mass, vitamin D and PTH status.
LS BMC SDS, lumbar spine bone mineral content standard deviation score; vitamin D deficiency < 25 nmol/L, insufficiency 25–50 nmol/L, 
normal  ≥  50 nmol/L. High PTH levels if  ≥  7.5 pmol/L, normal PTH if < 7.5 pmol/L. Vit D, N normal vitamin D; Vit D, ↓ if vitamin D deficient and 
insufficient; PTH, N if < 7.5 pmol/L; PTH, ↑ if  ≥  7.5 pmol/L. The number in figures show number of patients out of the total of 100 for each 
column, in a specific category.
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mean LS BMC SDS varied from T0 to T1 and T2 ( − 0.51; 
− 0.64; − 0.56; p = 0.178 repeated way ANOVA). In the 
37 children who had a baseline LS BMC SDS > − 0.5, 29 
(78%) assessments showed a fall in BMC SDS compared to 
previous assessment. Conversely, in the 35 children who 
had a poor baseline LS BMC SDS < − 0.5, 12 (35%) assess-
ments showed a decline in BMC SDS compared to previous 
assessment (Figure 2D, E, F).
Determinants of initial bone mineral content
Significant determinants of basal LS BMC SDS were iden-
tified using hierarchical multiple regression (backward 
method). The significant determinants of initial LS BMC SDS 
were height SDS and supplemental feeding (coded 0 and 1 – 
for presence of supplemental feeding). All determinants cor-
related inversely with LS BMC SDS (Table 2). Variables that 
did not reach statistical significance were: age, gender, age 
at peak height velocity and peak height velocity (in centi-
metres), initial BMI SDS, vitamin D level, PTH, FEV1%, oral 
corticosteroids and impaired glucose tolerance.
Determinants of change in bone mineral 
content
To identify predictors of change for bone mineral content, 
annualised ∆ LS BMC SDS was used as dependent variable 
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Figure 2: The dynamics of vitamin D and LS BMC SDS at T0, T1 and T2.
(A–C) The dynamics of vitamin D at T0, T1 and T2 separated in (A), (B) and (C), in regards to baseline vitamin D status. T0, baseline, first DXA 
assessment; T1, second DXA assessment; T2, third DXA assessment; vitamin D deficiency defined when vitamin D levels were < 50 nmol/L 
(20 ng/mL), insufficiency if the vitamin D levels were between 52.5 and 72.5 nmol/L (21–29 ng/mL), and normal if vitamin D level  ≥  75 nmol/L 
(30 ng/mL). (D–F) The dynamics of LS BMC SDS at T0, T1 and T2 separated in (D), (E) and (F), in regards to baseline status in LS BMC SDS, 
lumbar spine bone mineral content standard deviation score. Three classes of LS BMC SDS: > 0.5; between − 0.5 and 0.5, and  ≤  − 0.5.
Table 2: Determinant of initial and change in bone mineral 
 content-results from hierarchical multiple linear regression 
( backward method).
  β   95% CI
Determinants of baseline LS BMC SDSa   
 Height SDS   − 0.414   − 0.652; − 0.176
 Supplemental feeding   − 0.637   − 1.861; − 0.660
Determinants of annualised ∆ LS BMC 
SDSb
   
 ∆ FEV1%   0.010   0.003; 0.014
 Initial vitamin D   0.014   0.001; 0.016 
 Second BMI SDS   0.105   0.006; 0.176 
95% CI, 95% confidence intervals; BMI SDS, body mass index 
 standard deviation score (Cole T. et al. 2000); LS BMC SDS, lumbar 
spine bone mineral content standard deviation score; ∆ FEV1%, 
 difference in forced expiratory volume in 1 s percent, between sub-
sequent assessments. Supplemental feeding was coded 0 if absent 
and was coded 1 if supplemental feeding was present. a Hierarchical 
regression model (backward method) R = 0.492, adjusted R 
square = 0.202, p < 0.001. bHierarchical regression model (backward 
method) R = 0.467, adjusted R square = 0.297, p = 0.017.
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in a hierarchical multiple linear regression (backward 
method).
The significant determinants of initial LS BMC SDS 
were ∆ FEV1%, second BMI SDS, and initial vitamin D 
level. All determinants correlated directly with annual-
ised ∆LS BMC SDS, as shown in Table 2. Variables that did 
not reach statistical significance were: age, gender, peak 
height velocity (in centimetres), age at peak height veloc-
ity, initial BMI SDS, second vitamin D level, initial and 
second FEV1%, initial, second and change in PTH, oral 
corticosteroids, supplemental feeding, impaired glucose 
tolerance and segregation status.
Discussion
Increased life expectancy for people with CF requires a 
greater need for monitoring conditions such as CF-related 
low bone mineral mass. Several cross-sectional reports 
have reported low bone mass in both post-pubertal 
children and adults with CF, although adults tend to be 
more affected [18–22]. Monitoring bone mass and pro-
viding preventive care are necessary from childhood 
through adolescence to minimise CF-related bone disease 
in adults with CF [8]. Although several cross-sectional 
studies have examined bone mass in children with CF 
[8, 23], longitudinal determinants of bone health have 
rarely been studied [24–26]. Thus, we aimed to assess the 
extent of bone health problems in a contemporary cohort 
of children with CF, to assess changes in bone health to 
better understand determinants of bone mineral content 
as assessed by DXA.
The pubertal spurt of children with CF did not appear 
to be delayed and similar to the recent report by Bournez 
et  al. [27]. In accordance with several previous studies, 
the PHV was impaired in both sexes in our cohort [28, 29]. 
However, as we did not have data on the Tanner pubertal 
stage, we cannot accurately conclude this.
Over 60% of children in our study were vitamin D 
insufficient or deficient at baseline. Other studies report 
variable percentages for vitamin D deficiency ranging from 
19% to 97% in children with CF [30, 31]. The prevalence 
may be influenced by several factors such as sun expo-
sure, geographical position, supplementation regimen, 
disease severity, age and other medications. Guidelines 
from the Cystic Fibrosis Foundation’s Consensus Confer-
ence on Bone Health recommend that vitamin D2  sup-
plementation is required to maintain 25OHD levels  ≥  30 
ng/mL [9]. However, maintaining 25OHD in individuals 
with CF at this level may be challenging. Low 25OHD may 
lead to a rise in serum PTH [32] and although different 
PTH thresholds (45 to 75 pg/mL) are used to define hyper-
parathyroidism [31, 33] elevated PTH levels are strongly 
associated with increased bone resorption and bone loss 
[34]. Almost 12% of children with CF in this study had a 
PTH above 7.5 pmol/L (70 pg/mL), similar with findings in 
another analysis in the general population [31]. The find-
ings in our study also suggest that a combined assessment 
of 25OHD with PTH may be more beneficial in assessing 
the risk of vitamin D deficiency to bone health. Addition-
ally, the presence of supplemental feeding was strongly 
associated with a lower BMC.
Overall, most children showed a fall in LS BMC SDS 
over the period of follow-up. The prevalence of bone 
mineral density (BMD) z-scores below − 1 SD was 10% in 
our study, but it has been reported to be as high as 85% 
in some adult CF studies [9]. On the other hand, there are 
some cross-sectional surveys showing that pre-pubertal 
children with CF do not have a bone mineral deficit com-
pared with a weight- and sex-matched control groups 
[35–38]. The reasons for the discrepancy in the findings 
include: differences in measurement and analytic tech-
niques that adjust for impaired growth and maturation 
in CF patients, disease severity, reference data, and the 
lack of consensus in defining impaired bone health in 
children.
Factors influencing bone health in CF patients are 
partly nutritional, due to possibly low caloric intake; 
vitamin  D, vitamin K, calcium, and essential fatty acid 
depletion. Muscle mass plays an important role in achiev-
ing and maintaining bone health, however decreased 
muscle mass is almost universal in CF [39, 40]. Chronic 
inflammation, and glucocorticoid treatment further 
threaten bone health in CF [9]. The factors found to influ-
ence the change in BMC in our study, included FEV1%, 
and poorer nutritional status as described by BMI and low 
vitamin D. Several cross-sectional studies have demon-
strated a positive correlation between bone mineral mass 
and both FEV1% and BMI [8, 9, 39]. Our longitudinal study 
has also confirmed this association, but larger longitudi-
nal studies are needed to further clarify this.
Chronic pulmonary infection in individuals with CF 
may be a contributory factor in the long-term complica-
tions of low weight and bone disease [40]. The segregation 
status was not found as a significant factor in bone mass 
change.
This study had several limitations. Factors that were 
not assessed in the current study that may require further 
exploration in a prospective study include the incidence 
of hospitalisations and fractures, gonadal function, 
Shwachman score, cumulative steroid therapy, other 
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medication, Vitamin K sufficiency and pancreatic insuf-
ficiency. The study did not assess the physical exercise 
practice that is a known factor to influence bone mass. 
The genotype- phenotype interactions, in relevance to the 
bone mass, were not assessed in this study. As this is a 
retrospective longitudinal study it has some limitations. 
The children with CF had a DXA scan as a routine part 
of bone health screening, however, there may have been 
some selection bias as those with repeated scans had a 
lower baseline bone content ( −0.34 vs −0.15) or other risk 
factors for bone loss that rendered them inherently differ-
ent from those who did not have follow-up scans. Thus 
the results from the first DXA assessment (100 children) 
may be more representative of a CF population, while 
the findings from the follow-up DXA assessments may be 
more representative of children with CF that are at risk for 
lower bone mass.
Conclusions
In summary, in this large single centre longitudinal study, 
children with CF showed a gradual fall in bone mass SDS 
and the likelihood of this fall was greater in those with 
worse respiratory disease, poorer nutritional status and a 
low vitamin D when combined with a high PTH.
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